Prevalence and outcome of dysnatremia in patients with COVID-19 compared to controls
Open Access
- 1 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 184 (3) , 409-418
Abstract
Objective: The pandemic of coronavirus disease (COVID-19) has rapidly spread globally and infected millions of people. The prevalence and prognostic impact of dysnatremia in COVID-19 is inconclusive. Therefore, we investigated the prevalence and outcome of dysnatremia in COVID-19. Design: The prospective, observational, cohort study included consecutive patients with clinical suspicion of COVID-19 triaged to a Swiss Emergency Department between March and July 2020. Methods: Collected data included clinical, laboratory and disease severity scoring parameters on admission. COVID-19 cases were identified based on a positive nasopharyngeal swab test for SARS-CoV-2, patients with a negative swab test served as controls. The primary analysis was to assess the prognostic impact of dysnatremia on 30-day mortality using a cox proportional hazard model. Results: 172 (17%) cases with COVID-19 and 849 (83%) controls were included. Patients with COVID-19 showed a higher prevalence of hyponatremia compared to controls (28.1% vs 17.5%, P < 0.001); while comparable for hypernatremia (2.9% vs 2.1%, P = 0.34). In COVID-19 but not in controls, hyponatremia was associated with a higher 30-day mortality (HR: 1.4, 95% CI: 1.10–16.62, P = 0.05). In both groups, hypernatremia on admission was associated with higher 30-day mortality (COVID-19 - HR: 11.5, 95% CI: 5.00–26.43, P < 0.001; controls - HR: 5.3, 95% CI: 1.60–17.64, P = 0.006). In both groups, hyponatremia and hypernatremia were significantly associated with adverse outcome, for example, intensive care unit admission, longer hospitalization and mechanical ventilation. Conclusion: Our results underline the importance of dysnatremia as predictive marker in COVID-19. Treating physicians should be aware of appropriate treatment measures to be taken for patients with COVID-19 and dysnatremia.Keywords
This publication has 40 references indexed in Scilit:
- Hyponatremia and anti-diuretic hormone in Legionnaires’ diseaseBMC Infectious Diseases, 2013
- Mortality and Serum SodiumClinical Journal of the American Society of Nephrology, 2011
- Severe Hypernatremia Correction RateMortality in Hospitalized PatientsThe American Journal of the Medical Sciences, 2011
- Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency departmentBMC Pulmonary Medicine, 2009
- Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort studyBMC Pulmonary Medicine, 2008
- Copeptin: a new and promising diagnostic and prognostic markerCritical Care, 2008
- Hyponatremia in Community-Acquired PneumoniaAmerican Journal of Nephrology, 2007
- Incidence and Prevalence of HyponatremiaThe American Journal of Medicine, 2006
- Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate managementNephrology Dialysis Transplantation, 2005
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997